Trial Profile
Cangrelor Versus Ticagrelor In Patients With Acute Myocardial Infarction Complicated With Initial Cardiogenic Shock
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Cangrelor (Primary) ; Ticagrelor
- Indications Cardiogenic shock; Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Acronyms DAPT-SHOCK-AMI
- 22 Jan 2024 Planned End Date changed from 1 May 2024 to 1 Jan 2025.
- 22 Jan 2024 Planned primary completion date changed from 1 Jun 2023 to 1 Jan 2024.
- 03 Oct 2022 Planned number of patients changed from 304 to 550.